Speaker Profile
M.D., Clinical Professor of Medicine, Yale School of Medicine
Biography
William K. Oh, M.D., is currently the Director of Precision Medicine at Yale Cancer Center and a Professor of Medicine (Medical Oncology) at Yale School of Medicine, roles he assumed in October 2024. As part of a newer initiative at Yale, he is focused on building a cohesive program in precision cancer medicine that integrates basic and translational science, clinical trials, and Smilow Cancer Hospitals Precision Medicine Tumor Board. A central goal of his work is to increase the routine use of molecular and genetic testing for all cancer patients to improve outcomes. Dr. Oh is also dedicated to delivering multidisciplinary care for prostate cancer patients, a priority he has maintained for over 25 years. He has been recognized as a Top Doctor by Castle Connolly, New York Magazine, and Super Doctors. Additionally, he continues his commitment to teaching and advancing research in the field.Previously, Dr. Oh was a Clinical Professor of Medicine at Icahn School of Medicine. He is an internationally recognized medical oncologist with extensive experience in clinical and translational research, holding leadership roles in both academia and industry. He has authored more than 350 articles, reviews, books, and book chapters related to genitourinary cancers. Dr. Oh has conducted numerous clinical cancer trials and served in key invited roles for ASCO, ACS, and AUA. He has also held the position of Chief Medical Officer for Sema4, a genomics and health intelligence company, as well as the Prostate Cancer Foundation.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Shannon Turley, Amgen
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
Fireside Chat: Immune Tolerance to Cure
• Mary E. Brunkow, ISB - 2025 Nobel Laureate
• Lee Hood, Phenome Health
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
• Vadim Koshkin, UC San Francisco
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesanim, United Theranostics
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Chair: Levi Garraway, Roche
